Share Twitter LinkedIn Facebook Email Mark Levis, MD, PhD, talks about new information about gilteritinib in FLT3 mutated acute myeloid leukemia (AML) at Annual Meeting 2018.
Transforming AML Treatment: The Breakthrough Precision and Speed of Dr. Gabriel Mannis, MD on the Notable Platform Acute Myelogenous Leukemia 1 Min Read
Molecular Changes and Patient Stratification – Parrish Phimes, MD Acute Myelogenous Leukemia 2 Mins Read
